India to cut 354 generic prices Nov 2

15 October 2006

India's Chemicals and Fertilizers Minister, Ram Vilas Paswan has announced that pharmaceutical companies will "drastically reduce" the prices of 354 generic drugs from November 2. Mr Paswan gave no further details, reports the Marketletter's correspondent.

The low-cost generic drugs, carrying the price, manufacturing and expiry dates in Hindi and English, will be available in medical stores from that date, he said. The Minister said the pharmaceutical companies have also agreed to do away with local taxes on drug sales, making them even less expensive for consumers.

As well as ensuring drug price cuts, the Ministry, which oversees the pharmaceutical industry, has also decided to set up a countrywide drug bank from January 1 next year that would provide medicines free of cost to people living below the poverty line (Marketletter October 2). Mr Paswan did not elaborate.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight